Nektar Therapeutics (NASDAQ:NKTR) has a beta value of 0.57 and has seen 2.6 million shares traded in the last trading session. The company, currently valued at $257.72M, closed the last trade at $1.40 per share which meant it gained $0.07 on the day or 5.26% during that session. The NKTR stock price is -37.86% off its 52-week high price of $1.93 and 70.71% above the 52-week low of $0.41. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.6 million shares traded. The 3-month trading volume is 1.13 million shares.
The consensus among analysts is that Nektar Therapeutics (NKTR) is Buy stock at the moment, with a recommendation rating of 2.71. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Nektar Therapeutics (NASDAQ:NKTR) trade information
Sporting 5.26% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NKTR stock price touched $1.40 or saw a rise of 4.76%. Year-to-date, Nektar Therapeutics shares have moved 147.79%, while the 5-day performance has seen it change 10.24%. Over the past 30 days, the shares of Nektar Therapeutics (NASDAQ:NKTR) have changed 9.38%. Short interest in the company has seen 6.04 million shares shorted with days to cover at 5.64.
Wall Street analysts have a consensus price target for the stock at $18.5, which means that the shares’ value could jump 92.43% from current levels. The projected low price target is $6.0 while the price target rests at a high of $24.0. In that case, then, we find that the current price level is -1614.29% off the targeted high while a plunge would see the stock gain -328.57% from current levels.
Nektar Therapeutics (NKTR) estimates and forecasts
Figures show that Nektar Therapeutics shares have outperformed across the wider relevant industry. The company’s shares have lost -6.67% over the past 6 months, with this year growth rate of 41.38%, compared to 18.60% for the industry. Revenue growth from the last financial year stood is estimated to be -10.60%.
7 analysts offering their estimates for the company have set an average revenue estimate of 18.28M for the current quarter. 7 have an estimated revenue figure of 17.87M for the next ending quarter. Year-ago sales stood 24.14M and 23.89M respectively for this quarter and the next, and analysts expect sales will shrink by -24.30% for the current quarter and -10.60% for the next.
Earnings growth for 2024 is a modest 44.88% while over the next 5 years, the company’s earnings are expected to decrease by -7.30%.
NKTR Dividends
Nektar Therapeutics is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Insiders own 1.06% of the company shares, while shares held by institutions stand at 73.94% with a share float percentage of 74.73%. Investors are also buoyed by the number of investors in a company, with Nektar Therapeutics having a total of 169.0 institutions that hold shares in the company. The top two institutional holders are DEEP TRACK CAPITAL, LP with over 17.88 million shares worth more than $22.17 million. As of 2024-06-30, DEEP TRACK CAPITAL, LP held 9.1789% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 15.16 million shares as of 2024-06-30. The firm’s total holdings are worth over $18.79 million and represent 7.7823% of shares outstanding.
